Filing summary
Business context and reporting period: iSpecimen Inc. filed this Form 8-K on October 9, 2026, reporting results from its special stockholders’ meeting held that day. This is a governance update, not a quarterly or annual financial report.
Financial position and performance
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating financial results. It does not provide the financial terms or expected financial impact of the approved asset acquisition.
Meeting results and material developments
As of the August 12, 2026 record date, 2,518,590 common shares were entitled to vote. A total of 1,287,547 shares, approximately 51.1%, were present in person or by proxy, constituting a quorum.
| Proposal | Result | Votes for | Votes against | Abstentions |
|---|---|---|---|---|
| Nasdaq approval for shares underlying pre-funded warrants and related adjustments | Approved | 779,705 | 33,092 | 160 |
| Reverse stock split, at a ratio from 1-for-10 to 1-for-100 | Adjourned to October 30, 2026 | Final result pending | Final result pending | Final result pending |
| Nasdaq approval for potential future convertible or equity-linked financing | Approved | 782,722 | 30,099 | 136 |
| Asset acquisition from Foldlab AI Ltd. | Approved | 791,600 | 21,269 | 88 |
| Adjournment authority | Approved | 1,150,689 | 112,799 | 24,059 |
The future-financing proposal covers potential issuances during the 12 months following stockholder approval, including securities with conversion or exercise prices reflecting discounts of up to 80% from the applicable lowest volume-weighted average price. The filing notes that the pre-funded warrant proposal and future-financing proposal may permit issuance of substantial additional shares. The asset acquisition approval includes issuing common stock as partial consideration under an agreement dated September 4, 2026.
Outlook, risks, and items to verify
- The reverse-split vote remains open; the adjourned meeting is scheduled for October 30, 2026, at 10:00 a.m. Eastern Time. The company said it will report the final result in a subsequent Form 8-K.
- Verify the final reverse-split vote and whether the board sets a split ratio within the approved range.
- Review the proxy statement and transaction documents for the asset acquisition’s terms, consideration, and expected impact; those details are not provided in this filing.
- Assess potential dilution from the approved warrant-related issuance and future financing authority, including the disclosed potential for deeply discounted pricing.